TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy which has progressed on standard therapy or for which no standard therapy is available.~* Measurable disease per RECIST v1.1.~* Adequate bone marrow, renal and liver functioning~Exclusion Criteria:~* CNS primary malignancies, active seizure disorder or spinal cord compression, or carcinomatous meningitis.~* History of any of the following toxicities associated with a prior immunotherapy:~  * Grade 3 immune mediated adverse event that was considered related to previous immunotherapy and required immune suppressive therapy;~ * Grade 2 hepatic function related adverse event that persisted more than 1 week, was considered related to immunotherapy, or required treatment discontinuation or immunosuppressive therapy~* Any of the following within the 12 months prior to registration: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack and 6 months for deep vein thrombosis or pulmonary embolism.~* History of or known presence of extensive, disseminated/bilateral or Grade 3 or 4 interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, or pulmonary fibrosis, but not including a history of prior radiation pneumonitis. Patients with clinically significant lung disease requiring oxygen therapy (eg, COPD).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-05082566 +MK-3475 (Type: EXPERIMENTAL): PF-05082566 +MK-3475

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Adult subjects with previously treated recurrent CLL who have measurable lymphadenopathy~* Require therapy for CLL~* Have experienced CLL progression \< 24 months since the completion of the last prior therapy~* Currently not sufficiently fit to receive cytotoxic therapy because of chemotherapy-induced bone marrow damage or comorbidities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Idelalisib + rituximab (Type: ACTIVE_COMPARATOR): Participants will receive idelalisib plus rituximab
- Placebo + rituximab (Type: PLACEBO_COMPARATOR): Participants will receive placebo to match idelalisib plus rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Boys were classified into 5 different Tanner stages (I-V) according to the criteria of Feingold D. In Atlas of physical diagnosis. Pediatric endocrinology. 2nd ed. Philadelphia. WB Saunders; 1992, pp. 16-19. For comparison, adult men were also recruited.~Exclusion Criteria:~* Individuals with chronic illness or disorder, i.e. hepatic and renal complications, epilepsy, pneumonia, asthma, orchitis, hernia, cryptorchidism, mental retardation, etc. were excluded from this study

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tanner Stage I (Type: EXPERIMENTAL): A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 9.5 µg/BW.
- Tanner Stage II (Type: EXPERIMENTAL): A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 11.50 µg/BW.
- Tanner Stage III (Type: EXPERIMENTAL): A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 12.67 µg/BW.
- Tanner Stage IV (Type: EXPERIMENTAL): A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 15.11 µg/BW.
- Tanner stage V (Type: EXPERIMENTAL): A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 20.5 µg/BW.
- Adult Group (Type: EXPERIMENTAL): A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 1 µg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Chronically infected with Hepatitis C Virus (HCV) genotype 1~* Treatment naive or treatment non-responders or treatment intolerant; and not co-infected with HIV or Hepatitis B Virus~* HCV RNA viral load of ≥10\*5 IU/mL~* BMI 18 to 35kg/m²~Exclusion Criteria:~* Any significant acute or chronic medical illness which is not stable or is not controlled with medication and not consistent with Hepatitis C Virus infection~* HIV and/or HBV positive~* Major surgery within 4 weeks of study drug administration and any gastrointestinal surgery that could impact the absorption of study drug~WOCBP will be enrolled as in-patient for 16 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Daclatasvir (1 mg), once daily~or~Matching Placebo, once daily
- Group 2 (Type: ACTIVE_COMPARATOR): Daclatasvir (10 mg), once daily~or~Matching Placebo, once daily
- Group 3 (Type: ACTIVE_COMPARATOR): Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily
- Group 4 (Type: ACTIVE_COMPARATOR): Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily
- Group 5 (Type: ACTIVE_COMPARATOR): Group 5: Active Comparator~Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily
- Group 6 (Type: ACTIVE_COMPARATOR): Group 6: Active Comparator~Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Evolocumab on Coronary Endothelial Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants of either gender who are \>21 years of age (no upper age limit)~* HIV (Human Immunodeficiency Virus) positive and taking stable Anti-Retroviral Therapy (ART), no change in regimen in last 3 months)~* Undetectable HIV viral load (plasma HIV RNA concentration, RNA=Ribonucleic Adic)~* Abnormal coronary endothelial function on MRI (Magnetic Resonance Imaging) at baseline (\<5% change in coronary cross sectional area during isometric handgrip exercise as compared to resting value).~* Lipids at screening visit: Fasting LDL-C \>70 mg/dL (LDL-C=Low Density Lipoprotein Cholesterol); fasting TG\<500 mg/dL (TG=Triglycerides)~* Permission of treating physician~Exclusion Criteria:~* Patients unable to understand the risks, benefits, and alternatives of participation and give meaningful consent.~* Patients with contraindications to MRI such as implanted metallic objects (pre-existing cardiac pacemakers, cerebral clips),~* History of a recent cardiovascular or cerebrovascular events or procedure (e.g. myocardial infarction, stroke, transient ischemic attack, angioplasty, Coronary artery bypass surgery) during the past 90 days.~* Subjects with prior exposure to evolocumab or another PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitor.~* Pregnant women or breastfeeding women. Women of childbearing potential (even if using oral contraceptive agents) or intention to breastfeed.~* History of alcoholism or drug addiction according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV criteria within 12 months prior to screening. Use of any recreational drugs within 6 months prior to screening.~* Renal impairment defined by estimated glomerular filtration rate \<45 ml/min.~* Moderate-severe hepatic disease (elevation in hepatic transaminases \>3x upper limit of normal, ULN) or direct bilirubin \>3.0 X ULN at screening.~* Cluster of differentiation 4 (CD4)\<200 cell/mm3~* Congestive heart failure, New York Heart Association functional class III or greater, or left ventricular ejection fraction measured by imaging known to be \<30%. (Imaging not required for study inclusion).~* History of allergic or anaphylactic reaction to any therapeutic monoclonal antibody (IgG protein) or molecules made of components of monoclonal antibodies~* Active phase hepatitis. Stable patients with hepatitis B or C infection \>3 years before randomization are eligible.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Evolocumab (Type: EXPERIMENTAL): All enrolled patients will receive evolocumab sq once a month for a total of two doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Employment and Reducing Recidivism Among Prison Offenders Via Virtual Interview Training Tool (MICHR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 25 years or older~* Identified as at moderate to high risk for reoffending with violent crimes (determined at the time of enrollment in the Vocational Village via the COMPAS Risk Assessment Classification Instrument \[60\])~* Within three months of their earliest release date~* Actively enrolled in a Vocational Village~* Have at least a 6th grade reading comprehension~Exclusion Criteria:~* Has uncorrected hearing or visual problem that prevents him or her from using the training~* Has a medical illness that compromises their cognition (for example, moderate to severe traumatic brain injury).

- Gender: MALE
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Services as usual + Virtual Reality Job Interview Training (Type: EXPERIMENTAL): In addition to the services as usual, participants will participate in Virtual Reality Job Interview Training.
- Services as Usual (Type: ACTIVE_COMPARATOR): Study participants will be receiving their Vocational Village services as usual that may include but not limited to vocational skill training, and social skill training.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with ectocervical CIN1 or CIN2 as verified by local pathology (biopsy) obtained within the last month~* Satisfactory colposcopy examination including:~  * visibility of entire transformation zone including the squamocolumnar junction and~ * visibility of entire lesion margin~* Negative endocervical os by colposcopy~* Colposcopical visible lesion at visit 2, before treatment~* Patients with an average sized uterine cervix (approximately 27mm diameter) suitable for application of the Klemcap~* Age 18 or above~* Written informed consent signed~Exclusion Criteria:~* Previous treatment of CIN or invasive disease~* Lesion(s) extending to the vaginal vault~* Atypical glandular cells (AGC) or adenocarcinoma in situ (AIS) on cytology, malignant cells on cytology or histology or other suspicion of either micro-invasive or invasive disease~* Suspicion of endocervical disease on colposcopy~* Current severe pelvic inflammatory disease, severe cervicitis, or other severe gynaecological infection as per colposcopy and clinical examination~* Undiagnosed vaginal bleeding~* History of toxic shock syndrome~* Known or suspected porphyria~* Known allergy to hexaminolevulinate or similar compounds (e.g. methyl aminolevulinate or aminolevulinic acid)~* Pregnancy, or intention to become pregnant during the study period~* Nursing~* Childbirth or miscarriage within six weeks of enrolment~* Use of heart pacemaker~* Participation in other clinical studies either concurrently or within the last 30 days~* Risk of poor protocol compliance. Patient participation should be considered with respect to living far away from the hospital, plans for moving to another city/state, frequent travelling, planning to become pregnant, drug abuse/alcoholic, difficult working hours, family obligations, other illness (e.g. psychiatric), etc.~* Unwillingness to use adequate birth control (not abstinence) from screening until last PDT~* Patient is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HAL 5% with illumination (Type: EXPERIMENTAL): HAL PDT 5%
- HAL 1% with illumination (Type: EXPERIMENTAL): HAL PDT 1%
- HAL 0.2% with illumination (Type: EXPERIMENTAL): HAL PDT 0.2%
- Placebo ointment without illumination (Type: PLACEBO_COMPARATOR): Placebo without illumination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~This study was open to all subjects who:~* Completed participation in LEVP2005-1/A (NCT00289211) and were not participating in LEVP2005-1/B (NCT01005888), any time after the 3-day telephone follow-up~* Completed participation in LEVP2005-1/B any time after the final prophylactic therapy in Part B~* Were enrolled but not randomized in LEVP2005-1/A after Part A was closed~* Were excluded from LEVP2005-1 for any of the following reasons:~  * Pregnancy or lactation~ * Age less than 6 years~ * Narcotic addiction~ * Presence of anti-C1INH autoantibodies~* Were not enrolled in LEVP2005-1 after enrollment in LEVP2005-1 was closed, under the following circumstances:~  * Had a diagnosis of HAE: evidence of a low C4 level plus either a low C1INH antigenic level or a low C1INH functional level, or~ * Had a known HAE-causing C1INH mutation, or~ * Had a diagnosis of HAE based on a strong family history of HAE as determined by the principal investigator~Exclusion Criteria:~* History of allergic reaction to C1INH or other blood products~* Participated in any other investigational drug study within the past 30 days~* Received blood or a blood product in the past 60 days other than C1INH-nf

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-label C1INH-nf (Type: EXPERIMENTAL): 1,000 Units (U) of C1INH-nf administered intravenously. If there was no response to treatment 60 minutes after the first dose, a second 1,000 U dose could be administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is willing and able to complete the micturition diary and questionnaires correctly~* Patient has symptoms of overactive bladder for ≥ 3 months~* Patient experiences frequency of micturition on average ≥ 8 times per 24-hour period during the 3-day micturition diary period~* Patient must experience at least 3 episodes of urgency (grade 3 or 4) with or without incontinence, during the 3-day micturition diary period~Exclusion Criteria:~* Patient is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control~* Patient has significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor~* Patient has an indwelling catheter or practices intermittent self-catheterization~* Patient has diabetic neuropathy~* Patient has evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs~* Patient receives non-drug treatment including electro-stimulation therapy~* Patient has severe hypertension~* Patient has a known or suspected hypersensitivity to tolterodine, other anticholinergics, YM178, other beta-adrenoreceptor (ß-AR) agonists, or lactose or any of the other inactive ingredients~* Patient has been treated with any investigational drug or device within 30 days (90 days in the UK for all clinical studies except 178-CL-046)~* Patient had an average total daily urine volume \> 3000 mL as recorded in the 3-day micturition diary period~* Patient has serum creatinine \>150 umol/L, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 2x upper limit of normal range (ULN), or gamma-glutamyl transpeptidase (γ-GT) \> 3x ULN~* Patient has a clinically significant abnormal electrocardiogram (ECG)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mirabegron 50 mg (Type: EXPERIMENTAL): Participants received mirabegron 50 mg tablets and matching tolterodine extended release (ER) placebo capsules orally once a day for 12 months.
- Mirabegron 100 mg (Type: EXPERIMENTAL): Participants received mirabegron 100 mg tablets and matching tolterodine ER placebo capsules orally once a day for 12 months.
- Tolterodine ER 4 mg (Type: ACTIVE_COMPARATOR): Participants received tolterodine ER 4 mg capsules and matching mirabegron placebo tablets orally once a day for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed Hodgkin's lymphoma of any histology~* Unfavorable disease required~  * Clinical stage IIIA, IIIB, IV, or IIB (non-bulky)~ * Locally extensive stage I or II with either of the following:~    * Mediastinal mass greater than 1/3 the maximum intrathoracic diameter~   * Two or more extranodal sites~PATIENT CHARACTERISTICS:~Age:~* 18 to 60~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* No prior malignancy except nonmelanomatous skin cancer~* No significant concurrent illness that precludes protocol participation~PRIOR CONCURRENT THERAPY:~* No prior treatment for Hodgkin's lymphoma~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Combination Chemotherapy (Stanford V) (Type: EXPERIMENTAL): A combination chemotherapy regimen consisting of mechlorethamine, doxorubicin hydrochloride, vinblastine, vincristine, bleomycin, etoposide and prednisone, administered on a compressed schedule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete